- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04582929
Neubotulinum Toxin Injection in Cerivical Dystonia (NTCD)
24-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 50 Unit of Neubotulinum Toxin Type A (Neuronox) and 100 Unit of Neubotulinum Toxin Type A (Neuronox) Injection for Cervical Dystonia in Thai Patients
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
Lampang, Thailand, 52000
- Lampang Hospital
-
Surat Thani, Thailand, 84000
- Suratthani Hospital
-
Ubon Ratchathani, Thailand, 34000
- Sappasitthiprasong Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
•The subject has to grant permission to enter into the study by signing and dating the informed consent form before completing any study-related procedure such as any assessment or evaluation not related to the normal medical care of the subject.
Able to give written inform consent and retained one copy of the consent form
- Male or female subject, aged between 18 - 100 years old.
- Subject diagnosed to be cervical dystonia.
- Female subject in good health and sexually active was instructed by the investigator to avoid pregnancy during the study and to use condom or other contraceptive measure if necessary. The subject was required to have a negative urine pregnancy test before being eligible for the study. (At each of the subsequent visit, a urine pregnancy test was performed).
- Subject judged to be reliable for compliance for taking medication and capable of recording the effects of the medication and motivated in receiving benefits from the treatment.
- Subject should undergo a normal physical and neurological examination TWSTRS, CDIP-58, SF36, and CES-D • during the whole study period
Exclusion Criteria:
- The subject was pregnant or lactating.
- The subject was a female at risk of pregnancy during the study and not taking adequate precautions against pregnancy.
- The subject had a known hypersensitivity to any of the test materials or related compounds.
- The subject was unable or unwilling to comply fully with the protocol.
- The subject received any unlicensed drug within the previous 6 months.
- Treatment with investigational drug (s) within 6 months before the screening visit. • The subject had previously entered in this study.
Subject with past history of botulism, other neuromuscular disorder (e.g. myasthenia gravis, Lambert - Elton Syndrome)
- Subject with significant medical / neurological / psychiatric disorders such as blood dyscrasia, thrombocytopenia, rheumatoid arthritis, congestive heart failure, coronary artery heart diseases, dementia, psychosis, or other conditions which could influence the clinical trial.
- Known history of drug abuse (narcotic (s), cafergot, or others) or drug (botulinum toxin type A) allergy.
- Unable to cooperate fill-up TWSTRS, CDIP-58, SF36, and CES-D • Patient who planned to schedule elective surgery during the study.
- The used of aminoglycoside antibiotics and curare were not allowed during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 unit of Neubotulinum Toxin Type A (Neuronox)
50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
|
Neuronox ® 50 or 100 unit intramuscular injection
Other Names:
|
Experimental: 100 unit of Neubotulinum Toxin Type A (Neuronox)
100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
|
Neuronox ® 50 or 100 unit intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toronto Western Spasmodic Torticollis Rating scale ( TWSTRS)
Time Frame: 24 week
|
WSTRS ranged( 0-85 by summation of all 3 sub- scales ) higher represent a worse outcome TWSTRS Sub- scale includes TWSTRS-Total severity scale ( maximum 35 points) TWSTS-Disability scale (maximum 30 points) TWSTS-Pain scale (maximum 20 points) |
24 week
|
Cervical Dystonia Impact Profile 58 ( CDIP-58)
Time Frame: 24 week
|
Cervical Dystonia Impact Profile-58 items composed of 8 sub-scale Total score by summation of 8 subscale higher represent a worse outcome Analysis both total score (range 58-290 points) And sub-scale analysis composed of Head and neck symptoms ( 6 items ; 6-30 points) Pain and discomfort ( 5 items ; 5-25 points) Upper limb activity ( 9 items ; 9-45 points) Walking ( 9 items ; 9-45 points) Sleep ( 4 items ; 4-20 points) Annoyance ( 8 items ; 8-40 points) Mood (7 items ; 7-35 points) Psychosocial functioning ( 10 items ; 10-50 points)
|
24 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparesion the quality of life 36 item ( SF 36)
Time Frame: 24 week
|
Comparesion the quality of life (SF 36) pre- and post- 12 and 24 week ttreatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) this score has special formula calculation
|
24 week
|
Depression scale measured by Center of Epidemiologic Study of Depression 20 item ( CES-D 20)
Time Frame: 24 week
|
Comparesion of CES-D pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) Score ranged from 20-80 points higher represent a worse outcome
|
24 week
|
Depression scale measured by Patient Health Questionnaire Depression Scale (PHQ-9)
Time Frame: 24 week
|
Comparesion of PHQ-9 pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) There is the special scale calculation for diagnosis Major depressive disorder, Other depressive disorder and others,higher points /score represent a worse outcome ranged 0-27 points plus 3 points Total summation of 5-9 points indicate Minimal symptoms, 10-14 Minor depression ++ or Dysthymia* or Major depression, mild , 15-19 points Major depression, moderately severe ≥ 20 Major depression, severe (range PHQ 9 0-27 ) higher represent a worse outcome |
24 week
|
Clinical Global Impression of Changed ( CGIC)
Time Frame: 24 week
|
Comparesion of CGIC pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) (range -3 to 3 points: -3,-2,-1,0,1,2,3)
|
24 week
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Kongsaengdao S, Maneeton B, Maneeton N. Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study. Neuropsychiatr Dis Treat. 2017 Jan 10;13:127-132. doi: 10.2147/NDT.S116325. eCollection 2017.
- Kongsaengdao S, Maneeton N, Maneeton B. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Neuropsychiatr Dis Treat. 2018 Apr 26;14:1119-1124. doi: 10.2147/NDT.S152252. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Dystonia
- Dystonic Disorders
- Torticollis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins, Type A
Other Study ID Numbers
- A-02-2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Dystonia
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCervical Dystonia, PrimaryFrance
-
University of FloridaBachmann Strauss Dystonia & Parkinson Foundation, Inc.Completed
-
University Hospital, MontpellierTerminatedSpasticity | Isolated Cervical Dystonia | Complex DystoniaFrance
-
Duke UniversityAmerican Academy of NeurologyNot yet recruiting
-
University of Colorado, DenverCompleted
-
University of FloridaAmerican Brain Foundation; NeuroneticsCompletedDystonia | Primary Cervical DystoniaUnited States
-
University Hospital, LilleCompletedIdiopathic Cervical DystoniaFrance
-
IpsenCompletedIdiopathic Cervical DystoniaBelgium, France, United Kingdom, Portugal, Germany, Australia, Czechia, Netherlands, Russian Federation
-
Fondazione Don Carlo Gnocchi OnlusUnknownCervical Dystonia,PrimaryItaly
-
University of FloridaDystonia Medical Research FoundationTerminated
Clinical Trials on Neuronox ® Injection
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
-
Versailles HospitalJennifer YEUNG (neurologist); Aurélien MAURIZOT (angiologist); Simon CHABAY (angiologist) and other collaboratorsCompletedCerebral InfarctionFrance
-
Macrocure Ltd.ICON plc; Amarex Clinical Research; ARANZ MedicalCompletedLower Extremity Chronic Ulcers in DiabeticsUnited States, Israel, Canada
-
Green Cross CorporationCompleted
-
DeNova ResearchGalderma R&DCompletedDeformity of Nasal CartilageUnited States
-
Medy-ToxCompletedMuscle SpasticityKorea, Republic of
-
Medy-ToxCompletedGlabellar Frown LinesKorea, Republic of
-
Sarepta Therapeutics, Inc.CompletedNeoplasmsUnited States